Accurate Dose Delivery Research Articles

3D gel dosimeter assessment for end-to-end geometric accuracy determination of the online adaptive workflow on the 1.5 T MR-linac

Background and purpose:During an end-to-end (E2E) test on the online workflow of the MR-linac, the performance of the treatment starting from the acquisition of pre-treatment MRI scans and ending with dose delivery is quantified. In such a test, the geometrical accuracy of the entire workflow is assessed. Ideally, the 3D geometrical accuracy of dose delivery on an MR-linac should be assessed using dosimeters that provide 3D dose distributions. Gel dosimeters, for instance, have proven to be valuable tools for evaluating 3D dose distributions on an MR-linac. In this study, we investigated the use of 3D gel dosimeters for the assessment of the 3D geometrical accuracy and reproducibility of the adaptive procedure on an MR-linac in an E2E verification. Materials and methods:All measurements were performed on a clinical Unity MR-linac using 3D gel dosimeters in an anthropomorphic head phantom. Film measurements were performed as a reference dosimeter. An online adapt-to-shape procedure was performed for each measurement. Results:The geometric accuracy and reproducibility of the gel dosimeter measurements were high, and similar to all in-plane film measurements. The largest shift found was 0.3 mm for the gel dosimeter, and 0.6 mm for the in-plane film measurements. The 3D displacement vectors of the gel dosimeter showed similar uncertainties as the in-plane film 2D displacement vectors. Conclusions:Gel dosimeters can be used for the assessment of the 3D end-to-end geometric accuracy of an MR-linac.

Monitoring and Control of Irradiation with Carbon Ions During Radiobiological Experiments at the RBS Experimental Set-Up

The RBS experimental set-up has been working in every accelerator session of the U-70 accelerator complex since 2015. The main users of the set-up are radiobiologists and physicians. The direction of research is radiobiological experiments with extracted beams of accelerated carbon ions and preclinical studies aimed at the development of domestic methods of ion therapy. The requirements for irradiation of samples with carbon ions are very high: irradiation uniformity is no worse than 95%, positioning accuracy is no worse than 0.1 mm, dose delivery accuracy is no worse than ±2.5%. The article describes the instruments and devices that are used to support radiobiological experiments at the RBS installation: a plane-parallel ionization chamber, a mosaic ionization chamber, a water phantom with a 3D movement system, a 6-axis table, a degrader, a laser positioning system, clinical dosimeters. Programs for working with this equipment and archiving the data obtained are described.

Estimation of weighted computed tomography dose index (CTDIw) in megavoltage computed tomography (MVCT)

Abstract Introduction Advanced technologies in radiation treatment deliveries require high accuracy and precision in setup before treatment to get accurate dose delivery for planned target volumes. During imaging procedures, patients are getting extra doses from kilovoltage computed tomography (KVCT) and megavoltage computed tomography (MVCT). Computed tomography dose index is an important dosimetric parameter to know the degree of radiation-induced side effects. Aim The main aim of this study is to quantify the dose received by patients during MVCT imaging procedures, weighted computed tomography dose index (CTDIw), volume computed tomography dose index (CTDIvol) and dose length product (DLP). Methods and materials This study has been performed on Radixact X9 LINAC machine with 6MV flattening filter-free (FFF) photon beam for treatment and imaging with 3.5 MeV average photon energy. CTDIw and dose length product (DLP) have been calculated for different scanning lengths 18 cm, 10 cm and 0.7 cm with fine, normal and coarse modes with standard imaging A1SL1 ion chamber, cheese phantom and tomoelectrometer. Results CTDIw, CTDIvol, and DLP have been calculated with cheese phantom using A1SL1 ion chamber. CTDIw for 0.7 cm is 2.16 cGy, 1.14 cGy and 0.77 cGy for fine normal and coarse modes, respectively. Conclusion CTDIw is a dosimetric index to know the dose levels at center and periphery of patient according to scan length. It gives an idea about how much additional dose is received by the patient during the imaging procedures. High pitch gives the lesser absorbed dose. DLP gives the knowledge about stochastic effects from radiation to patients after MVCT.

Investigation of pelvic floor influence on prostate displacement in image-guided radiotherapy.

The uncertainty of target location during prostate cancer radiotherapy plays an important role in accurate dose delivery and radiation toxicity in adjacent organs. This study analyzed displacement correlations between the prostate and pelvic floor. We retrospectively analyzed registration results from 467 daily cone-beam computed tomography (CT) in 12 patients with prostate cancer who received radiation therapy. We analyzed prostate displacement and the pelvic floor relative to the pelvic bone's anatomy in the translational and rotational directions and identified statistical correlations. The systematic (Σ) and random (σ) displacements of the prostate in the three translational directions, anterior-posterior (AP), superior-inferior (SI), and right-left (RL), were 1.49 ± 1.45, 2.10 ± 1.40, and 0.24 ± 0.53 mm, respectively, and in the rotational directions of the pitch, roll, and yaw were 2.10 ± 2.02°, 0.42 ± 0.74°, and 0.42 ± 0.64°, respectively. The pelvic floor displacements were 2.37 ± 1.96, 2.71 ± 2.28, and 0.47 ± 0.84 mm in the AP, SI, and RL directions, respectively, and 0.93 ± 1.49°, 0.98 ± 1.28 °, and 0.87 ± 0.94° in the pitch, roll, and yaw directions, respectively. Additionally, there were statistically significant correlations between the displacement of the prostate and pelvic floor in the AP and SI directions, with correlation coefficients (r) of 0.74 (p < 0.001) and 0.69 (p < 0.001), respectively. The movement of the pelvic floor may be an important factor that causes prostate displacement, affecting the accuracy of radiotherapy. Therefore, it is necessary to take appropriate measures to ensure that the pelvic floor muscle tension is as consistent as possible in the treatment' CT scan and daily treatment.

Evaluation of patient-specific quality assurance for fractionated stereotactic treatment plans with 6 and 10MV photon beams in beam-matched linacs.

Beam-matched linear accelerators (LA's) require accurate and precise dosimetry for fractionated stereotactic treatment. In this study, the beam data were validated by comparing the three-beam-matched LA's measured data and the vendor reference data. Upon its validation, the accuracy of the volumetric dose delivery for eighty patient-specific fractionated stereotactic treatment plans was evaluated. Measurements of the percentage depth dose (PDD), beam profiles, output factors (OFs), absolute output, and dynamic multi-leaf collimator (MLC) transmission factors for 6MV and 10MV flattening filter (FF) and flattening filter-free (FFF) photon beams were obtained from three-beam-matched LA's. The patient-specific quality assurance evaluation for all eighty plans was performed using PTW Octavius 1000 SRS™ array detectors for two-dimensional (2D) fluence measurement. The following 2D gamma passing criteria were used: 1%/1mm, 2%/1mm, 1%/2mm, 2%/2mm and 3%/2mm. In all three LA's, gamma analysis for PDD and profile were above 97% with gamma criteria of 1%/1mm. The differences OFs, absolute output, and dynamic MLC transmission factors were less than ± 1% of base value. For all eighty cases, the median passing rates on the three LA's were above 76%, 88%, 92%, 96%, and 98% for the above-mentioned gamma criteria of the three LA's. The beam-matched LA's showed good agreement between the measured and treatment planning system (TPS) calculated values for fractionated stereotactic VMAT plans with 6MV and 10MV (FF and FFF) photon beams. Patients can be shifted and treated on any beam-matched linac without the need of re-planning.

Clinical implementation and patient-specific quality assurance solutions for real-time target tracking and dynamic delivery in Radixact synchrony.

The installation and testing of the first Radixact with Synchrony system in Colombia marked a significant milestone in Latin America's medical landscape. There was a need to devise a robust quality assurance protocol to comprehensively evaluate both dose delivery and motion tracking accuracy. However, testing experiences under clinical conditions have not been extensively reported. Additionally, there are limited recommended measuring devices for Synchrony evaluation. To validate and implement an alternative setup for dynamic-PSQA while testing Synchrony's functionality under clinical scenarios, including real-patient motion traces, and to provide guidance to new centers undergoing clinical implementation of Helical Synchrony. This approach involves using the Iba miniPhantomR with strategically placed fiducial markers for configuring Gafchromic-films and array-based setups. When paired with the CIRS Dynamic Platform, this enables an innovative dynamic setup with trackable features for Synchrony delivery testing. Assessment scenarios, including compensation (M1S1) and no-motion compensation (M1S0), were evaluated using 2D-gamma pass rate analysis with multiple clinical gamma criteria. The Synchrony-Simulation feature was used to assess pre-treatment performance and capture the patient's target motion pattern. Synchrony for common clinical cases with patient's motion-traces was validated. The results for M1S0 and M1S1 demonstrated consistency with previous studies evaluating Synchrony functionality. Analysis using different gamma criteria unveiled dosimetric differences and impacts across various motion ranges. The application of effective kV-dose subtraction for array-based methods is of upmost importance when evaluating dynamic-PSQA with stringent gamma-criteria. However, no significant kV-dose impact on EBT3-Film was detectable. Two implemented configurations for dynamic-PSQA setups were validated and successfully integrated into our clinic. We addressed both the benefits and limitations of array-based and film-based methods. The functionality and limitations of Synchrony were evaluated using the proposed setups. The potential utility of Synchrony-Simulation, along with the proposed patient-case classification table, can offer valuable support for new users during the clinical implementation of Synchrony treatments.

Injectability of high concentrated suspensions using model microparticles

Administration of high-concentrated suspension formulations (i.e., solid particles dispersed in a liquid vehicle) can be limited due to their greater propensity for needle occlusion. The physical interaction between the solid phase (i.e., particles), the vehicle (i.e., flow field), and injection devices could result in the formation of particle bridging or filtering, posing a major risk in dose delivery accuracy and injectability. Here, given the limited understanding on how clogging initiates in syringe and needle delivery systems, we report an experimental approach to fully characterize the transient injection behavior of suspensions. In particular, we first established a custom fluorescence tagging and imaging technique with integrated force sensor to enable visual observation of local particle concentrations and plunger force monitoring throughout injection. Then, we investigated the effects of key formulation properties and device parameters including particle concentration and morphology, carrier viscosity, injection rate, needle and syringe sizes, and tissue backpressure on the incidence of suspension particle jamming and needle clogging. We performed systematic benchmark studies demonstrating that increasing needle inner diameter (ID) and particle density considerably reduced clogging risk, while increasing vehicle viscosity, particle size, and tissue backpressure significantly increased clogging. The experimental framework presented is amenable to quantifying clogging risk in drug-loaded particle suspensions and provides a guideline to make informed decisions on the tradeoffs between creating particles for pharmaceutical impact and feasibility of injection delivery.

Calculation of Dose Perturbation in Radiotherapy of Head and Neck Tumors Due to the Presence of Dental Implants: A Monte Carlo Study

Purpose: The presence of a dental implant across the irradiation beam has the potential to perturb the dose distribution. In this study, the effect of different commercial dental implants on dose distribution was investigated in electron beam therapy. Materials and Methods: The Varian 2100 C/D linear accelerator (Linac) head was modeled precisely with proper components for electron mode (6 and 9 MeV) by MCNPX 2.6.1 and was benchmarked according to the International Atomic Energy Agency (IAEA) protocol, TRS -398. Dose distribution was calculated for Six different implant materials, including Titanium, Titanium alloy, Zirconia (Y-TZP), Zirconium oxide, Alumina, and PolyetherEtherKetone (PEEK), and for Four different scenarios. Results: The highest and lowest increasing doses occurred for Y-TZP (114.44% and 108.69% for 6 and 9 MeV, respectively) and PEEK (104.85% and 98.84% for 6 and 9 MeV, respectively) directly in front of the implant, respectively. By removing an implant from the jaw, an increasing dose was not seen, but an increasing dose occurred behind its depths in the bone region (31.81 %). Conclusion: The amount of dose perturbation due to the dental implant's presence depends on the beam energy, mass density, and atomic numbers of implants. Maximum and minimum increased doses were estimated for Y-TZP and PEEK implants, respectively. Considering the correction factors due to the presence of high density and atomic number dental implants are essential to estimate the accurate dose delivery in radiotherapy with electron beams.

Dosimetric Comparison between the HyperArc and Conventional VMAT in Cervical Spine Stereotactic Radiosurgery.

Background: This research aims to evaluate the usability of the HyperArc (HA) technique in stereotactic radiosurgery for cervical spine metastasis by comparing the dosimetry of the target and organs at risk, specifically the spinal cord, between HA and VMAT and conventional volumetric modulated arc therapy (VMAT). Methods: A RANDO® phantom and QFix EncompassTM and support system were used to simulate three target types (A, B, and C) based on RTOG0631 guidelines. Treatment plans included one VMAT and two HyperArc techniques with different SRS NTO values (100 and 250). Dosimetric parameters such as conformity index (CI), homogeneity index (HI), R50, and spinal cord sparing were analyzed. Gamma analysis was performed using portal dosimetry to validate the dose delivery accuracy. Results: HyperArc plans demonstrated higher conformity, sharper dose fall-off, and improved quality assurance (QA) results compared to VMAT plans. HA with SRS NTO 250 showed even better results in terms of conformity, dose fall-off, and spinal cord dose reduction (V10 and Dmax) compared to HA with SRS NTO 100. Although the mean gamma passing rates were slightly lower, all plans achieved rates above 95%. Conclusion: The findings suggest that HA provides superior dosimetric benefits over VMAT and could be effectively utilized for cervical spine radiation therapy.

Investigation of the linear accelerator low dose rate mode for pulsed low-dose-rate radiotherapy delivery

Purpose. Pulsed volumetric modulated arc therapy (VMAT) was proposed as an advanced treatment that combines the biological benefits of pulsed low dose rate (PLDR) and the dosimetric benefits of the intensity-modulated beams. In our conventional pulsed VMAT technique, a daily fractional dose of 200 cGy is delivered in 10 arcs with 3 min intervals between the arcs. In this study, we are testing the feasibility of pulsed VMAT that omits the need to split into ten arcs and excludes any beam-off gaps. Methods. The study was conducted using computed tomographic images of 24 patients previously treated at our institution with the conventional PLDR technique. Our newly installed Elekta machine has a low dose rate option on the order of 25 MU min−1. PLDR requires an effective dose rate of 6.7 cGy min−1 with attention being paid to the maximum dose received within any point within the target not to exceed 13 cGy min−1. The quality of treatment plans was judged based on dose-volume histograms, isodose distribution, dose conformality to the target, and target dose homogeneity. The dose delivery accuracy was assessed by measurements using the MatriXX Evolution 2D array system. Results. All cases were normalized to cover 95% of the target volume with 100% of the prescription dose. The average conformity index was 1.03 ± 0.08 while the average homogeneity index was 1.05 ± 0.02. The maximum reported dose rate at any point within the target was 10.44 cGy min−1. The mean dose rate for all pulsed VMAT plans was 6.88 ± 0.1 cGy min−1. All cases passed our gamma analysis with an average passing rate of 99.00% ± 0.48%. Conclusion. The study showed the applicability of planning pulsed VMAT using Eclipse and its successful delivery on our Elekta linac. Pulsed VMAT using the machine’s low dose rate mode is more efficient than our previous pulsed VMAT delivery.

Visual Dose Monitoring for Whole Breast Radiation Therapy Treatments via Combined Cherenkov Imaging and Scintillation Dosimetry

PurposeThis study investigates scintillation dosimetry coupled with Cherenkov imaging for in vivo dose monitoring during whole breast radiotherapy (WBRT). Given recent observations of excess dose to the contralateral breast (CB), in vivo dosimetry (IVD) could help ensure accurate dose delivery and decrease risks of secondary cancer. This work presents a rapid, streamlined alternative to traditional IVD, providing direct visualization of measurement location relative to the treatment field on the patient. Methods and Materials10 WBRT patients consented under an IRB-approved protocol were monitored with scintillation dosimetry and always-on Cherenkov imaging, on both their treated and CB for one to three fractions. Scintillator dosimeters, small plastic discs 1mm thick and 15mm in diameter, were calibrated against optically-stimulated luminescent dosimeters (OSLDs) to generate an integral output-to-dose conversion, where integral output is measured in post-processing through a custom fitting algorithm. The discs have been extensively characterized in a previous study for various treatment conditions including beam energy and treatment geometry. ResultsN=44 dosimetry measurements were evaluated, including 22 treated breast and 22 CB measurements. Following integral output-to-dose calibration, in vivo scintillator dosimeters exhibited high linearity (R2=0.99) with paired OSLD readings across all patients. The difference between scintillation and OSLD dose measurements averaged 2.8% of the prescribed dose, or an absolute dose difference of approximately 7 cGy. ConclusionsIntegration of scintillation dosimetry with Cherenkov imaging offers an accurate, rapid alternative for in vivo dose verification in WBRT, circumventing the limitations of conventional point dosimeters. The additional benefit of visualizing measurement locations relative to the treatment field provides users an enhanced understanding of results and allows for detection of high dose gradients. Future work will explore the applicability of this technique across a broader range of radiotherapy treatments, aiming to streamline IVD practices.

Evaluation of TOPAS MC tool performance in optical photon transport and radioluminescence-based dosimetry

Radiation therapy plays a pivotal role in modern cancer treatment, demanding precise and accurate dose delivery to tumor sites while minimizing harm to surrounding healthy tissues. Monte Carlo simulations have emerged as indispensable tools for achieving this precision, offering detailed insights into radiation transport and interaction at the subatomic level. As the use of scintillation and luminescence dosimetry becomes increasingly prevalent in radiation therapy, there arises a need for validated Monte Carlo tools tailored to optical photon transport applications. In this paper, an evaluation process of the TOPAS (TOol for PArticle Simulation) Monte Carlo tool for Cerenkov light generation, optical photon transport and radioluminescence based dosimetry is presented. Three distinct sources of validation data are utilized: one from a published set of experimental results and two others from simulations performed with the Geant4 code. The methodology employed for evaluation includes the selection of benchmark experiments, making use of opt3 and opt4 Geant4 physics models and simulation setup, with observed slight discrepancies within the calculation uncertainties. Additionally, the complexities and challenges associated with modeling optical photons generation through luminescence or Cerenkov radiation and their transport are discussed. The results of our evaluation suggests that TOPAS can be used to reliably predict Cerenkov generation, luminescence phenomenon and the behavior of optical photons in common dosimetry scenarios.

In vivo dosimetry with an inorganic scintillation detector during multi-channel vaginal cylinder pulsed dose-rate brachytherapy: Dosimetry for pulsed dose-rate brachytherapy

Background and purposeIn vivo dosimetry is not standard in brachytherapy and some errors go undetected. The aim of this study was to evaluate the accuracy of multi-channel vaginal cylinder pulsed dose-rate brachytherapy using in vivo dosimetry. Materials and methodsIn vivo dosimetry data was collected during the years 2019–2022 for 22 patients (32 fractions) receiving multi-channel cylinder pulsed dose-rate brachytherapy. An inorganic scintillation detector was inserted in a cylinder channel. Each fraction was analysed as independent data sets. In vivo dosimetry-based source-tracking was used to determine the relative source-to-detector position. Measured dose was compared to planned and re-calculated source-tracking based doses. Assuming no change in organ and applicator geometry throughout treatment, the planned and source-tracking based dose distributions were compared in select volumes via γ-index analysis and dose-volume-histograms. ResultsThe mean ± SD planned vs. measured dose deviations in the first pulse were 0.8 ± 5.9 %. In 31/32 fractions the deviation was within the combined in vivo dosimetry uncertainty (averaging 9.7 %, k = 2) and planning dose calculation uncertainty (1.6 %, k = 2). The dwell-position offsets were < 2 mm for 88 % of channels, with the largest being 5.1 mm (4.0 mm uncertainty, k = 2). 3 %/2 mm γ pass-rates averaged 97.0 % (clinical target volume (CTV)), 100.0 % (rectum), 99.9 % (bladder). The mean ± SD deviation was −1.1 ± 2.9 % for CTV D98, and −0.2 ± 0.9 % and −1.2 ± 2.5 %, for bladder and rectum D2cm3 respectively, indicating good agreement between intended and delivered dose. ConclusionsIn vivo dosimetry verified accurate and stable dose delivery in multi-channel vaginal cylinder based pulsed dose-rate brachytherapy.

Experiencing In-Vivo Dosimetry Verification in Malaysia: A Patient-Specific EPID-Based Approach

Real-time dosimetry is crucial for patient-specific quality assurance in radiotherapy facilities across Europe, and the same demand extends to advanced countries like Malaysia. Our study aimed to assess the need for in vitro diagnostic (IVD) testing in Malaysia, exploring the use of Electronic Portal Imaging Device (EPID)-based dose verification to simplify complex methods. In this research, we assessed the accuracy of in-vivo dose reconstruction using EPIgrayTM (DOSIsoft, Cachan, France) for 20 cohorts of patients who underwent breast and prostate Intensity-Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT), and compared the results with the dose calculated by the Treatment Planning System (TPS). Initially, we set a default tolerance level of 7-10% for dose acceptance. Our study found that the majority of patients in the cohort met the 10% tolerance level when validated with EPIgrayTM in vivo dosimetry. Specifically, 12 out of 15 patients who underwent VMAT treatment were within this tolerance range. Additionally, for IMRT treatment, 4 out of 6 patients achieved the 10% tolerance level. These initial findings demonstrate the potential of EPIgrayTM as a valuable tool for verifying in vivo dosimetry for advanced treatment techniques. For VMAT plans, more than 85% of the points were in agreement with the 10% tolerance level for 11 out of 15 patients. For IMRT plans, more than 90% of the points met the set tolerance level for 4 out of 15 patients. By understanding the agreement and variability of EPID-based IVD, we can further refine the utilization of EPID-based IVD as a relevant tool in ensuring accurate and reliable dose delivery during radiotherapy treatments.

Evaluation of dose delivery based on deformed CT using a commercial software for lung cancer

This study employed a commercial software velocity to perform deformable registration and dose calculation on deformed CT images, aiming to assess the accuracy of dose delivery during the radiotherapy for lung cancers. A total of 20 patients with lung cancer were enrolled in this study. Adaptive CT (ACT) was generated by deformed the planning CT (pCT) to the CBCT of initial radiotherapy fraction, followed by contour propagation and dose recalculation. There was not significant difference between volumes of GTV and CTV calculated from the ACT and pCT. However, significant differences in dice similarity coefficient (DSC) and coverage ratio (CR) between GTV and CTV were observed, with lower values for GTV volumes below 15 cc. The mean differences in dose corresponding to 95% of the GTV, GTV-P, CTV, and CTV-P between ACT and pCT were − 0.32%, 4.52%, 2.17%, and 4.71%, respectively. For the dose corresponding to 99%, the discrepancies were − 0.18%, 8.35%, 1.92%, and 24.96%, respectively. These differences in dose primarily appeared at the edges of the target areas. Notably, a significant enhancement of dose corresponding to 1 cc for spinal cord was observed in ACT, compared with pCT. There was no statistical difference in the mean dose of lungs and heart. In general, for lung cancer patients, anatomical motion may result in both CTV and GTV moving outside the original irradiation region. The dose difference within the original target area was small, but the difference in the planning target area was considerable.

Linac- and CyberKnife-based MRI-only treatment planning of prostate SBRT using an optimized synthetic CT calibration curve.

CT Hounsfield Units (HUs) are converted to electron density using a calibration curve obtained from physical measurements of an electron density phantom. HU values assigned to an MRI-derived synthetic computed tomography (sCT) may present a different relationship with electron density compared to CT HU. Correct assignment of sCT HU values is critical for accurate dose calculation and delivery. The goals of this work were to develop a sCT calibration curve using patient data acquired on a clinically commissioned CT scanner and assess for CyberKnife- and volumetric modulated arc therapy (VMAT)-based MR-only treatment planning of prostate SBRT. Same-day CT and MRI simulation in the treatment position were performed on 10 patients treated with SBRT to the prostate. Dixon in-phase and out-of-phase MRIs were acquired on a 3T scanner using a 3D T1-weighted gradient-echo sequence to generate sCTs using a commercial sCT algorithm. CT and sCT datasets were co-registered and HU values compared using mean absolute error (MAE). An optimized HU-to-density calibration curve was created based on average HU values across an institutional patient database for each of the four sCT tissue types. Clinical CyberKnife and VMAT treatment plans were generated on each patient CT and recomputed onto corresponding sCTs. Dose distributions computed using CT and sCT were compared using gamma criteria and dose-volume-histograms. For the optimized calibration curve, HU values were -96, 37, 204, and 1170 and relative electron densities were 0.95, 1.04, 1.1, and 1.7 for adipose, soft tissue, inner bone, and outer bone, respectively. The proposed sCT protocol produced total MAE of 94±20HU. Gamma values mean±std (min-max) were 98.9%±0.9% (97.1%-100%) and 97.7%±1.3% (95.3%-99.3%) for VMAT and CyberKnife plans, respectively. MRI-derived sCT using the proposed approach shows excellent dosimetric agreement with conventional CT simulation, demonstrating the feasibility of MRI-derived sCT for prostate SBRT treatment planning.

4D in vivo dosimetry for a FLASH electron beam using radiation-induced acoustic imaging

Objective. The primary goal of this research is to demonstrate the feasibility of radiation-induced acoustic imaging (RAI) as a volumetric dosimetry tool for ultra-high dose rate FLASH electron radiotherapy (FLASH-RT) in real time. This technology aims to improve patient outcomes by accurate measurements of in vivo dose delivery to target tumor volumes. Approach. The study utilized the FLASH-capable eRT6 LINAC to deliver electron beams under various doses (1.2 Gy pulse−1 to 4.95 Gy pulse−1) and instantaneous dose rates (1.55 × 105 Gy s−1 to 2.75 × 106 Gy s−1), for imaging the beam in water and in a rabbit cadaver with RAI. A custom 256-element matrix ultrasound array was employed for real-time, volumetric (4D) imaging of individual pulses. This allowed for the exploration of dose linearity by varying the dose per pulse and analyzing the results through signal processing and image reconstruction in RAI. Main Results. By varying the dose per pulse through changes in source-to-surface distance, a direct correlation was established between the peak-to-peak amplitudes of pressure waves captured by the RAI system and the radiochromic film dose measurements. This correlation demonstrated dose rate linearity, including in the FLASH regime, without any saturation even at an instantaneous dose rate up to 2.75 × 106 Gy s−1. Further, the use of the 2D matrix array enabled 4D tracking of FLASH electron beam dose distributions on animal tissue for the first time. Significance. This research successfully shows that 4D in vivo dosimetry is feasible during FLASH-RT using a RAI system. It allows for precise spatial (∼mm) and temporal (25 frames s−1) monitoring of individual FLASH beamlets during delivery. This advancement is crucial for the clinical translation of FLASH-RT as enhancing the accuracy of dose delivery to the target volume the safety and efficacy of radiotherapeutic procedures will be improved.

Comprehensively evaluating the performance of Elekta high-definition dynamic radiosurgery for hypofractionated stereotactic radiotherapy of multiple brain metastases

PurposeTo evaluate the dosimetric and delivery performance of Elekta high-definition dynamic radiosurgery (HDRS) in hypofractionated stereotactic radiotherapy (HSRT) for multiple brain metastases (BMs) by comparison with a conventional single-isocenter noncoplanar volumetric modulated arc therapy (VMAT) technique using the RayStation treatment planning system (TPS). Materials and methodsFrom June 2022 to October 2023, thirty-two patients (a total of 140 BMs) treated with HSRT (30–48 Gy/3-6f) via HDRS-based single-isocenter noncoplanar VMAT (HDRS-VMAT) were retrospectively selected for this study. Each patient was replanned using RayStation TPS-based single-isocenter noncoplanar VMAT (RayStation-VMAT). HDRS-VMAT and RayStation-VMAT plans were compared in terms of the gradient index (GI), conformity index (CI), normal brain tissue (NBT) dose exposure, monitor units (MUs), homogeneity index (HI), delivery accuracy, and beam-on time (BOT). ResultsCompared with the RayStation-VMAT plan, the HDRS-VMAT plan achieved superior CI (1.14 ± 0.09 vs. 1.23 ± 0.12, P < 0.001) and GI (5.23 ± 1.18 vs. 7.83 ± 2.75, p < 0.001) but had greater HI values. Compared with the RyaStation-VMAT plan, the HDRS-VMAT plan also yielded significantly lower NBT dose exposures (V23Gy, V21Gy, V18Gy, V12Gy and Dmean) but at the cost of increased MUs (3659.16 ± 1225.28 vs. 2536.23 ± 785.80, p < 0.001). The difference in BOTs was minimal (<1 min), which was not considered clinically significant. Furthermore, the HDRS-VMAT exhibited a higher gamma passing rate across all criteria (P < 0.001), particularly under stricter criteria (2%/1 mm), achieving an approximately 3% increase. ConclusionCompared with RaySation-VMAT, HDRS-VMAT offers superior target conformity, better NBT sparing, and higher delivery accuracy while maintaining comparable delivery efficiency. This represents a promising approach for HSRT of multiple BMs.

Stereotactic body radiation therapy (SBRT) for prostate cancer: Improving treatment delivery efficiency and accuracy

PurposeIn stereotactic body radiation therapy (SBRT) for prostate cancer, intrafraction motion is an important source of treatment uncertainty as it could not be completely smoothed through fractionation. Herein, we compared different arrangements and beam qualities for extreme hypofractionated treatments to minimize beam delivery time and so intrafractional errors. MethodsA retrospective dataset of 11 patients was used. Three volumetric modulated arc therapy (VMAT) beam arrangements were compared for a prescription dose of 40 Gy/5 fractions: two full arcs, 6 MV flattening filter free (FFF); one full arc, 6 MV FFF; one full arc, 10 MV FFF. A plan quality index was defined to compare achievement of the planning goals. Plan complexity was evaluated with the modulation factor. Dose delivery accuracy and efficiency were measured with patient-specific quality assurance plans. ResultsAll treatment plans fulfilled all dose objectives. No statistical differences were found both in plan quality and complexity. Very accurate dose delivery was achieved with the three arrangements, with mean γ passing rates >96.5 % (2 %/2 mm criteria). Slightly but significantly higher γ passing rates were observed with single-arc 6 MV FFF. Contrariwise, statistically significant reductions of the delivery time were obtained with single-arc geometries: the average delivery times were 1.6 min (−46.1 %) and 1.3 min (−56.2 %) for 6 and 10 MV FFF respectively. ConclusionsThe high-quality, very fast and accurate dose delivery of single-arc plans confirmed the suitability of this arrangement for prostate SBRT. In particular, the significant reduction of delivery time would improve treatment robustness against intrafraction prostate motion.

A feasibility study to predict 3D dose delivery accuracy for IMRT using DenseNet with log files.

This study aims to explore the feasibility of DenseNet in the establishment of a three-dimensional (3D) gamma prediction model of IMRT based on the actual parameters recorded in the log files during delivery. A total of 55 IMRT plans (including 367 fields) were randomly selected. The gamma analysis was performed using gamma criteria of 3% /3 mm (Dose Difference/Distance to Agreement), 3% /2 mm, 2% /3 mm, and 2% /2 mm with a 10% dose threshold. In addition, the log files that recorded the gantry angle, monitor units (MU), multi-leaf collimator (MLC), and jaws position during delivery were collected. These log files were then converted to MU-weighted fluence maps as the input of DenseNet, gamma passing rates (GPRs) under four different gamma criteria as the output, and mean square errors (MSEs) as the loss function of this model. Under different gamma criteria, the accuracy of a 3D GPR prediction model decreased with the implementation of stricter gamma criteria. In the test set, the mean absolute error (MAE) of the prediction model under the gamma criteria of 3% /3 mm, 2% /3 mm, 3% /2 mm, and 2% /2 mm was 1.41, 1.44, 3.29, and 3.54, respectively; the root mean square error (RMSE) was 1.91, 1.85, 4.27, and 4.40, respectively; the Sr was 0.487, 0.554, 0.573, and 0.506, respectively. There was a correlation between predicted and measured GPRs (P < 0.01). Additionally, there was no significant difference in the accuracy between the validation set and the test set. The accuracy in the high GPR group was high, and the MAE in the high GPR group was smaller than that in the low GPR group under four different gamma criteria. In this study, a 3D GPR prediction model of patient-specific QA using DenseNet was established based on log files. As an auxiliary tool for 3D dose verification in IMRT, this model is expected to improve the accuracy and efficiency of dose validation.